INMBINmune Bio, Inc.

$37M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$8M

Net Income

-$8M

EPS (Diluted)

$-0.89

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$24M

Total Liabilities

$860,543

Stockholders' Equity

$24M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$8M	-$12M	+37.7%
Net Income	-$8M	-$12M	+38.3%

INMB FY 2019 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena